Brief: YS Biopharma's PIKA Recombinant Covid-19 Vaccine Shows Superior Antibody Neutralization Responses Versus Inactivated Covid Vaccine In Phase II Head-To-Head Study

LakeShore Biopharma Co

27/03/2023 11:29

March 27 (Reuters) - Summit Healthcare Acquisition Corp
 YS.O :
    * YS BIOPHARMA'S PIKA RECOMBINANT COVID-19 VACCINE SHOWS
SUPERIOR
ANTIBODY NEUTRALIZATION RESPONSES VERSUS INACTIVATED COVID
VACCINE IN PHASE II HEAD-TO-HEAD STUDY
    * YS BIOPHARMA - TRIAL MET PRIMARY ENDPOINT OF SUPERIOR
IMMUNOGENICITY OF PIKA COVID-19 VACCINE VERSUS INACTIVATED
COVID-19 VACCINE
    * YS BIOPHARMA - TRIAL MET KEY SECONDARY ENDPOINT OF
SUPERIOR
IMMUNOGENICITY OF PIKA COVID-19 VACCINE VERSUS INACTIVATED
COVID-19 VACCINE

Source text for Eikon:  ID:nPn68qLCfa 
Further company coverage:  YS.O 

 ((Reuters.Briefs@thomsonreuters.com;))